Celgene (CELG) Tops Q2 EPS by 6c; Boosts FY16 Outlook

Celgene (NASDAQ: CELG) reported Q2 EPS of $1.44, $0.06 better than the analyst estimate of $1.38. Revenue for the quarter came in at $2.74 billion versus the consensus estimate of $2.7 billion.

REVLIMID® sales for the second quarter increased 18 percent year-over-year to $1,701 million and were driven by new patient market share gains and increased duration. U.S. sales of $1,080 million and international sales of $621 million increased 24 percent and 9 percent year-over-year, respectively.

GUIDANCE:

Celgene sees FY2016 EPS of $5.70-$5.75, versus prior guidance of $5.60-$5.70 and the consensus of $5.70. Celgene sees FY2016 revenue of $11.0 billion, versus prior guidance of $10.5-11.0 billion and the consensus of $11.0 billion.

For earnings history and earnings-related data on Celgene (CELG) click here.

You May Also Be Interested In

• Gilead Sciences (GILD) Misses Q1 EPS by 288c
• USCB Financial Holdings, Inc. (USCB) Tops Q1 EPS by 2c
• Business First Bancshares, Inc. (BFST) Misses Q1 EPS by 7c